- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07623837
Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) (GLANDY-EOM-VAL)
Prospective Multicenter Observational Study for Clinical Validation of AI-Based Quantitative Eye Movement Analysis Using Smartphone-Recorded 9-Gaze Videos
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Ocular motility is commonly evaluated using the 9-gaze examination, which relies on clinician observation and semi-quantitative grading. This approach is inherently subjective and can show inter-observer variability and limited sensitivity to subtle changes over time. Objective, quantitative assessment of eye movement remains an unmet clinical need, particularly for monitoring disease progression and treatment response.
Recent advances in artificial intelligence have enabled automated analysis of facial and ocular features from smartphone-recorded videos, offering the potential for reproducible quantitative measurement of eye movement. Glandy EOM is an investigational software-only medical device (SaMD) developed by THYROSCOPE INC. that processes smartphone-recorded 9-gaze videos to generate quantitative eye movement metrics. Glandy EOM has not yet received regulatory approval and is used for research purposes only in this study.
The study is a prospective, multicenter, multinational observational investigation designed to evaluate the clinical validity of Glandy EOM. The study population consists of adults with suspected or confirmed ocular motility abnormalities; healthy volunteers without any clinical indication for 9-gaze examination are not enrolled. Because eligibility is based on clinical suspicion or diagnosis of ocular motility abnormality rather than confirmed disease at enrollment, some participants may ultimately be clinically judged to have no abnormality on formal evaluation; such subjects remain part of the study population. Participants will undergo a single study visit consisting of (1) a standard clinical 9-gaze examination with clinician grading (-4 to +4), (2) a smartphone video recording performed with the assistance of a trained operator using a standardized setup, and (3) a patient self-recorded smartphone video acquired through the study mobile application.
For quantitative reference measurements, independent rater-derived measurements will be obtained from the recorded videos using a calibrated reference approach. A calibration marker of known size will be placed on the glabella during video acquisition to enable real-world scale estimation for the reference measurements. The calibration marker is used only for rater-based reference measurement and is not used by the AI algorithm.
The primary objective is to evaluate agreement between AI-derived quantitative eye movement metrics and rater-derived measurements of corneal center displacement, expressed as distance (mm) and angular deviation. Secondary objectives are to evaluate correlation between AI-derived metrics and clinician-assessed 9-gaze grading, and to evaluate whether AI-derived metrics obtained from patient self-recorded videos are comparable to those obtained from assistant-aided recordings. The investigational device is used solely for video acquisition and analysis and does not influence clinical decision-making during the study.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jaemin Park
- Número de teléfono: +82-52-264-4154
- Correo electrónico: jaemin.park@thyroscope.com
Ubicaciones de estudio
-
-
California
-
San Jose, California, Estados Unidos, 95134
- 3003 North First Street #221
-
Contacto:
- Jaemin Park
- Número de teléfono: +82-52-264-4154
- Correo electrónico: jaemin.park@thyroscope.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Adults of legal age of consent with suspected or confirmed ocular motility abnormalities, recruited at participating ophthalmology sites.
Some enrolled participants may ultimately be clinically judged to have no abnormality on formal evaluation; these subjects remain part of the study population and are not considered healthy volunteers.
Descripción
Inclusion Criteria:
- Adults who have reached the legal age of consent for research participation in the applicable jurisdiction.
- Subjects with suspected or known ocular motility abnormalities.
- Subjects who are able to understand and follow gaze instructions required for the 9-gaze examination, as judged by the investigator.
- Subjects who are able to undergo facial video recording using a smartphone.
- Subjects who provide written informed consent.
Exclusion Criteria:
- Conditions that prevent reliable detection of ocular landmarks in video recordings (e.g., severe ptosis, corneal opacity, or significant occlusion of the eyes).
- Ocular or facial conditions that, in the opinion of the investigator, may significantly interfere with image-based analysis.
- Subjects who are unable to comply with study procedures.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Ocular motility abnormality cohort (single cohort)
Adults with suspected or confirmed ocular motility abnormalities scheduled for clinical 9-gaze examination at participating ophthalmology sites.
No separate healthy-volunteer control cohort is enrolled; some participants may ultimately be clinically judged to have no abnormality on formal evaluation but remain part of the study population.
|
Glandy EOM is an investigational software-only medical device developed by THYROSCOPE INC. It has not yet received regulatory approval and is used for research purposes only in this study. Glandy EOM processes smartphone-recorded 9-gaze facial videos to generate AI-derived quantitative eye movement metrics:
AI outputs are generated for research analysis and are NOT used to guide real-time clinical decisions during the study. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Agreement between AI-derived and rater-derived corneal center displacement (distance, mm)
Periodo de tiempo: At study visit (single visit)
|
Agreement between AI-derived and rater-derived measurements of corneal center displacement expressed as distance (mm) across 9 gaze positions, assessed by intraclass correlation coefficient (ICC) and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Agreement between AI-derived and rater-derived angular deviation (degrees)
Periodo de tiempo: At study visit (single visit)
|
Agreement between AI-derived and rater-derived measurements of corneal center displacement expressed as angular deviation (degrees) across 9 gaze positions, assessed by ICC and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Linear association and absolute error vs. rater-derived reference
Periodo de tiempo: At study visit (single visit)
|
Linear association and absolute error between AI-derived and rater-derived measurements (both distance and angular deviation), assessed by Pearson correlation coefficient and mean absolute error (MAE), respectively.
|
At study visit (single visit)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between AI-derived metrics (assistant-aided recording) and clinician-assessed 9-gaze grading
Periodo de tiempo: At study visit (single visit)
|
Correlation between AI-derived eye movement metrics obtained from assistant-aided smartphone recordings and clinician-assessed 9-gaze grading (-4 to +4), assessed using Spearman correlation.
|
At study visit (single visit)
|
|
Correlation between AI-derived metrics (patient self-recorded) and clinician-assessed 9-gaze grading
Periodo de tiempo: At study visit (single visit)
|
Correlation between AI-derived eye movement metrics obtained from patient self-recorded smartphone videos and clinician-assessed 9-gaze grading (-4 to +4), assessed using Spearman correlation.
|
At study visit (single visit)
|
|
Agreement between AI-derived metrics from patient self-recorded vs. assistant-aided recordings
Periodo de tiempo: At study visit (single visit)
|
Agreement between AI-derived metrics obtained from patient self-recorded and assistant-aided smartphone videos, assessed using ICC and Bland-Altman analysis.
|
At study visit (single visit)
|
|
Linear association and absolute error: patient self-recorded vs. assistant-aided
Periodo de tiempo: At study visit (single visit)
|
Linear association and absolute error between AI-derived metrics from patient self-recorded and assistant-aided smartphone videos, assessed using Pearson correlation coefficient and mean absolute error (MAE).
|
At study visit (single visit)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del sistema endocrino
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Genéticas Congénitas
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Enfermedades de los ojos
- Enfermedades De Los Ojos Hereditarias
- Trastornos de la visión
- Trastornos sensoriales
- La enfermedad de Graves
- Exoftalmos
- Enfermedades Orbitales
- Coto
- Hipertiroidismo
- Enfermedades de los nervios craneales
- Enfermedades de la tiroides
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Oftalmopatía de Graves
- Trastornos de la motilidad ocular
- Estrabismo
- Diplopía
Otros números de identificación del estudio
- THYROSCOPE-EOM-2026-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .